Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps Novavax's COVID-19 vaccine showed fewer side effects than Pfizer's in a Utah study as FDA seeks more data before full approval decision.
BioNTech Surges On Summit's Coattails. But Can They Take On Merck? BioNTech is on the rise after Summit Therapeutics unveiled promising results for its PD-1- and VEGF-blocking drug.
Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study Novavax updated Covid vaccine showed fewer and milder side effects than Pfizer-BioNTech's in a Utah study.
Novavax Retail Traders Rally In Defense After RFK Jr.'s COVID-19 Vaccine Skepticism Sends Stock Tumbling Kennedy singled out the Novavax COVID-19 shot's single-antigen composition as the reason behind the delay in granting full approval.
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks. From vaccines to fluoride and beef tallow, here's where Robert F. Kennedy Jr. is making changes to health care.
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in July 2025.
BioNTech's 2025 Revenue View, Vaccine Policy Uncertainty Prompt Price-Target Cut: Retail Stays Cautiously Optimistic For the current year, BioNTech projected revenue of 1.7 billion euros to 2.2 billion euros, below the market consensus of 2.54 billion euros and a fall from last year's 2.75 billion euros.
BioNTech Se (BNTX) Q4 2024 Earnings Call Transcript BNTX earnings call for the period ending December 31, 2024.
BioNTech Surpasses Q4 Revenue Estimates BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.
Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday? Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (
NASDAQ:TSLA ) and Palantir Technologies, Inc.
Pfizer's COVID-19 Shot Partner BioNTech Reports Q4 Profit, But 2025 Guidance Falls Short On Expectations BioNTech's Q4 revenue beat estimates despite lower COVID-19 vaccine sales. The company advances oncology programs, with key data updates expected in 2025.
Why Moderna Stock Has Surged 20% This Week Despite Mixed News Recent news has been mixed with a patent win and loss in Germany and the U.S. But Moderna stock has risen markedly this week.
Nasdaq Falls Into Correction As Tariffs Roil Wall Street: What's Moving Markets Friday? All three major indices were red in Friday’s midday trading, with the S&P 500 and Nasdaq 100 down 1% and 1.24%, respectively, and on track for their worst weeks since September 2024.
FDA Places Clinical Hold On BioNTech's Early-Phase Trial For RNA-Based Malaria Vaccine BioNTech's malaria vaccine trial faces an FDA clinical hold. The company is addressing concerns and collaborating with regulators on next steps.
